<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03078010</url>
  </required_header>
  <id_info>
    <org_study_id>17-097</org_study_id>
    <nct_id>NCT03078010</nct_id>
  </id_info>
  <brief_title>Choosing the Best Antibiotic to Protect Friendly Gut Bacteria During the Course of Stem Cell Transplant</brief_title>
  <official_title>Rational Use of Broad-spectrum Antibiotics as Empiric Antibiotic Therapy in Febrile Neutropenia in Recipients of Allogeneic Hematopoietic Cell Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to see how different antibiotics affect the community of&#xD;
      friendly bacteria existing in the intestinal tract (gut). Under normal circumstances, these&#xD;
      friendly bacteria are not harmful and they help with normal bodily functions such as&#xD;
      digestion. When these bacteria are absent, several complications may occur, such as&#xD;
      infections with harmful bacteria or other inflammatory reactions, that can complicate the&#xD;
      stem cell transplant course. Treatment with antibiotics or chemotherapy is known to kill off&#xD;
      these friendly bacteria. In this study we compare the effects of different antibiotics on the&#xD;
      community of friendly bacteria in the gut.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to see how different antibiotics affect the community of&#xD;
      friendly bacteria existing in the intestinal tract (gut). Under normal circumstances, these&#xD;
      friendly bacteria are not harmful and they help with normal bodily functions such as&#xD;
      digestion. When these bacteria are absent, several complications may occur, such as&#xD;
      infections with harmful bacteria or other inflammatory reactions, that can complicate the&#xD;
      stem cell transplant course. Treatment with antibiotics or chemotherapy is known to kill off&#xD;
      these friendly bacteria. In this study we compare the effects of different antibiotics on the&#xD;
      community of friendly bacteria in the gut.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 10, 2017</start_date>
  <completion_date type="Anticipated">February 2022</completion_date>
  <primary_completion_date type="Anticipated">February 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This is a randomized open-label phase II study to assess the association between antibiotic treatment strategies and the change in the relative abundance of Clostridiales.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>measurement of fold-change in Clostridiales abundance</measure>
    <time_frame>7 +/- 2 days after initiation of piperacillin-tazobactam or cefepime</time_frame>
    <description>Fold change will be assessed 7 +/- 2 days after initiating antibiotic treatment for febrile neutropenia and will be compared to the pre-treatment specimen. Pre-treatment stool specimen will be collected between the time of enrollment Patients will be enrolled and infusion of allografts or first episode of neutropenic fever, whichever occurs first.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">144</enrollment>
  <condition>Intestinal Microbiome</condition>
  <condition>Febrile Neutropenia</condition>
  <arm_group>
    <arm_group_label>Piperacillin-tazobactam</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>cefepime</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Piperacillin-tazobactam</intervention_name>
    <description>piperacillin-tazobactam (4.5 gm IV q 6 hrs)</description>
    <arm_group_label>Piperacillin-tazobactam</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cefepime</intervention_name>
    <description>(2 gm IV q 8 hrs)</description>
    <arm_group_label>cefepime</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 18 years&#xD;
&#xD;
          -  Patients with any hematologic malignancy undergoing&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with severe allergies to piperacillin-tazobactam, cefepime, aztreonam or&#xD;
             vancomycin. Severe reactions include anaphylaxis and Stevens-Johnson syndrome&#xD;
             (SJS)/toxic epidermal necrolysis (TEN).&#xD;
&#xD;
          -  Patients with unconfirmed allergies to piperacillin-tazobactam, cefepime, aztreonam or&#xD;
             vancomycin can be evaluated by an Allergy/Immunology specialist, after which they may&#xD;
             become eligible by a consensus of the treating physician, trial investigator and and&#xD;
             the Allery&#xD;
&#xD;
          -  Prolonged antibiotic treatment ( ≥10 days, within 3 weeks of enrollment) as prevention&#xD;
             or suppression of an ongoing infection, where treatment involves gut-perturbing anti&#xD;
             anaerobic antibiotics&#xD;
&#xD;
          -  Patients known to be colonized with multi-drug resistant organisms or with history of&#xD;
             infection with multi-drug resistant organisms. Patients with history of infection with&#xD;
             extended-spectrum beta-lactamase producing organism.&#xD;
&#xD;
          -  Febrile patients&#xD;
&#xD;
          -  Patients with estimated glomerular filtration rate (eGFR) &lt; 30 mL/min/1.73m^2&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boglarka Gyurkocza, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Boglarka Gyurkocza, MD</last_name>
    <phone>212-639-2860</phone>
    <email>gyurkocb@mskcc.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Susan Seo, MD</last_name>
    <phone>212-639-3151</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hackensack Meridian Health</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michele Donato, MD</last_name>
      <phone>551-996-8297</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Boglarka Gyurkocza, MD</last_name>
      <phone>212-639-2860</phone>
    </contact>
    <contact_backup>
      <last_name>Susan Seo, MD</last_name>
      <phone>212-639-3151</phone>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mskcc.org/mskcc/html/44.cfm</url>
    <description>Memorial Sloan Kettering Cancer Center</description>
  </link>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>March 8, 2017</study_first_submitted>
  <study_first_submitted_qc>March 8, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 13, 2017</study_first_posted>
  <last_update_submitted>April 28, 2021</last_update_submitted>
  <last_update_submitted_qc>April 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Antibiotic</keyword>
  <keyword>piperacillin-tazobactam</keyword>
  <keyword>cefepime</keyword>
  <keyword>aztreonam</keyword>
  <keyword>17-097</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neutropenia</mesh_term>
    <mesh_term>Febrile Neutropenia</mesh_term>
    <mesh_term>Hyperthermia</mesh_term>
    <mesh_term>Fever</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tazobactam</mesh_term>
    <mesh_term>Piperacillin</mesh_term>
    <mesh_term>Cefepime</mesh_term>
    <mesh_term>Piperacillin, Tazobactam Drug Combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

